ECMO Systems

Extracorporeal membrane oxygenation (ECMO) is used as a hemodymanic support system to increase the flow of blood in the body to allow the heart and lungs to rest in critically ill patients. It is similar to a heart-lung by-pass machine used in open-heart surgery. It pumps and oxygenates a patient's blood outside the body with blood flowing through tubing to an artificial lung in to add oxygen and remove carbon dioxide. The blood is then the blood is warmed to body temperature and pumped back into the patient’s body. VA ECMO is connected to both a vein and an artery when there are problems with the heart and lungs. VV ECMO is connected to one or more veins, usually near the heart, and is used when the problem in the lungs.

The first COVID-19 patient in the world was supported by the new Abiomed Breethe OXY-1 System at Hackensack University Medical Center.

The first COVID-19 patient in the world was supported by the new Abiomed Breethe OXY-1 System at Hackensack University Medical Center.

News | ECMO Systems | February 25, 2021
February 25, 2021 — The first COVID-19 patient in the world was supported by the new Abiomed Breethe OXY-1 System, an...
Videos | ECMO Systems | February 16, 2021
An emotional reunion with COVID-19 patient Crystal Gutierrez and the clinicians and cardiologist who saved her life at ...
News | Coronavirus (COVID-19) | February 16, 2021
February 16, 2021 — Crystal Gutierrez, a young mother who earlier in 2020 fell seriously ill from the effects of COVID-...
COVID-19 related topics by far out-paced all other topics in cardiology in 2020 on the DAIC website. Several stories topped the list related to the cardiovascular issues with hydroxychloroquine being used as a treatment for the virus. Top new device technologies in 2020 included European approval of the Abbott Tendyne transcatheter mitral valve, FDA approval of Medtronic's new Micra AV pill-sized pacemaker, and FDA clearance of the first drug-eluting stent with short-duration dual-antiplatelet therapy.

COVID-19 related topics by far out-paced all other topics in cardiology in 2020 on the DAIC website. Several stories topped the list related to the cardiovascular issues with hydroxychloroquine being used as a treatment for the virus. Top new device technologies in 2020 included European approval of the Abbott Tendyne transcatheter mitral valve, FDA approval of Medtronic's new Micra AV pill-sized pacemaker, and FDA clearance of the first drug-eluting stent with short-duration dual-antiplatelet therapy (DAPT).

Feature | December 28, 2020 | Dave Fornell, Editor
Here are the top 25 best performing articles on the Diagnostic and Interventional Cardiology (DAIC) website from 2020....
The Abiomed Breethe OXY-1 System has received U.S. FDA 510(k) clearance. 
Feature | ECMO Systems | October 26, 2020
October 26, 2020 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Abiomed for an all-in-...
Flexible electronics have been developed to implant in patients to constantly monitor their cardiac condition.

Flexible electronics have been developed to implant in patients to constantly monitor their cardiac condition.

Feature | October 09, 2020 | Udi Nussinovitch M.D., Ph.D.
This is an overview of some of the biggest cardiology technology advances. These innovations are covered in more detail...
Videos | Coronavirus (COVID-19) | October 06, 2020
Ryan Barbaro, M.D., clinical assistant professor, pediatric critical care medicine, University of Michigan, and chair...

An ECMO procedure at Tufts Medical Center in Boston. The FDA cleared the use of ECMO support for COVID-19 patients in April 2020. A new review of patients treated with ECMO showed it had positive outcomes in the most severe COVID-19 patients. Photo by Dave Fornell

News | Coronavirus (COVID-19) | September 29, 2020
September 29, 2020 –  Extracorporeal membrane oxygenation (ECMO) support saved lives in past epidemics of lung-damaging...
Abiomed Impella is now authorized to treat critical ICU COVID-19 patients on ECMO who develop pulmonary edema or need cardiac decompensation from myocarditis. #COVID19 #SARScov2 #Impella

Abiomed Impella is now authorized to treat critical ICU COVID-19 patients on ECMO who develop pulmonary edema or need cardiac decompensation from myocarditis.

Feature | Coronavirus (COVID-19) | August 05, 2020 | Dave Fornell, Editor
August 5, 2020 — The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) this week for...
Thoracic findings in a 15-year-old girl with Multisystem Inflammatory Syndrome in Children (MIS-C). (a) Chest radiograph on admission shows mild perihilar bronchial wall cuffing. (b) Chest radiograph on the third day of admission demonstrates extensive airspace opacification with a mid and lower zone predominance. (c, d) Contrast-enhanced axial CT chest of the thorax at day 3 shows areas of ground-glass opacification (GGO) and dense airspace consolidation with air bronchograms. (c) This conformed to a mosai

Thoracic findings in a 15-year-old girl with Multisystem Inflammatory Syndrome in Children (MIS-C). (a) Chest radiograph on admission shows mild perihilar bronchial wall cuffing. (b) Chest radiograph on the third day of admission demonstrates extensive airspace opacification with a mid and lower zone predominance. (c, d) Contrast-enhanced axial CT chest of the thorax at day 3 shows areas of ground-glass opacification (GGO) and dense airspace consolidation with air bronchograms. (c) This conformed to a mosaic pattern with a bronchocentric distribution to the GGO (white arrow, d) involving both central and peripheral lung parenchyma with pleural effusions (black small arrow, d). image courtesy of Radiological Society of North America

Feature | Coronavirus (COVID-19) | June 30, 2020
In recent weeks, a multisystem hyperinflammatory condition has emerged in children in association with prior exposure...
Russian interventional cardiologist Alexey Pankov in full personal protective equipment (PPE) for a cath lab procedure in Moscow during the COVID-19 era. Right, an image of the COVID-19 virus from the National Institutes of Health (NIH).

Russian interventional cardiologist Alexey Pankov in full personal protective equipment (PPE) for a cath lab procedure in Moscow during the COVID-19 era. Right, an image of the COVID-19 virus from the National Institutes of Health (NIH). Novel coronavirus has turned out to have a sizable amount of cardiovascular involvement.

Feature | Coronavirus (COVID-19) | June 05, 2020 | Dave Fornell, Editor
It was originally thought novel coronavirus (COVID-19, SARS-CoV-2) was primarily a respiratory disorder, but as larger...
Rash on the skin of a child who has COVID-19 related multi-system inflammatory syndrome (MIS-C). Image copyright Damien Bonnet, M.D., Ph.D., courtesy of the American Heart Association. Coronavirus is linked with this Kawasaki-like inflammatory disease in children.

Rash on the skin of a child who has COVID-19 related multi-system inflammatory syndrome (MIS-C). The image is from  Damien Bonnet, M.D., Ph.D., Necker Hospital-Université, Paris, who was involved in a Circulation study published on MIS-C May 14. Image copyright Damien Bonnet, courtesy of the American Heart Association.

Feature | Coronavirus (COVID-19) | May 20, 2020 | Dave Fornell, Editor
(UPDATE December 28, 2020 — Newer articles and video on MIS-C can be found in the related content section at the bottom...
Abiomed Adds ECMO Cardiopulmonary Support to its Portfolio with the purchase of Breethe. The Breethe ECMO system. Abiomed invested in Breethe in mid-2019. Breethe has applied for 510(k) clearance by the Food and Drug Administration (FDA).

The Breethe ECMO system. Abiomed invested in Breethe in mid-2019. Breethe has applied for 510(k) clearance by the Food and Drug Administration (FDA).

News | ECMO Systems | May 01, 2020
May 1, 2020 — Abiomed, maker of the Impella heart pump, has acquired Breethe, developer of a novel extracorporeal...
LivaNova Modifies its ECMO Indications Beyond Six Hours to Address COVID-19. The FDA expanded the use indications for ECMO systems April 6 so tthey can be used beyond six hours and for use in COVID-19 patients in need of circulatory and pulmonary support.

The FDA expanded the use indications for ECMO systems April 6 so the systems can be used beyond six hours and for use in COVID-19 patients in need of circulatory and pulmonary support. Image shows an ECMO team at work at Tufts Medical Center in Boston in December 2019. Photo by Dave Fornell

News | Coronavirus (COVID-19) | April 23, 2020
April 23, 2020 – LivaNova PLC said the U.S. Food and Drug Administration (FDA) is now permitting the company to expand...
Videos | Coronavirus (COVID-19) | April 22, 2020
Justin Fried, M.D., Attending cardiologist at Columbia University Irving Medical Center, New York City, and assistant...